Stock Locations

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1708997- 43-6Upadacitinib Des Tosyl Impurity

● In Stock

Catalogue No.:	VE0027851
CAS No.:	1708997- 43-6
Mol. Formula:	C14H17N5
Mol. Weight:	255.32 g/mol

Request a quote

Add to RFQ list

Additional information on CAS 1708997- 43-6

Parent drug

Upadacitinib

IUPAC Name

8-((3R,4S)-4-ethylpyrrolidin-3-yl)-3H-imidazo[1,2-a] pyrrolo[2,3-e] pyrazine

Pharmacopeial Synonyms

N/A

Synonyms

N/A

Smiles

CC[C@H]1[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)CNC1

InChI

InChI=1S/C14H17N5/c1-2-9-5-15-6-10(9)12-7-17-13-8-18-14-11(19(12)13)3-4-16-14/h3-4,7-10,15-16H,2,5-6H2,1H3/t9-,10+/m1/s1

Description

Upadacitinib Des Tosyl Impurity (CAS 1708997-43-6) is a structurally related process impurity arising from incomplete tosyl protection removal during upadacitinib synthesis. It is characterized by mass spectrometry and retention behavior consistent with des-tosylated analogs and commonly monitored by validated HPLC and LC-MS methods to support impurity profiling and batch release. Typical control measures include reaction optimization, purification by crystallization or preparative chromatography, and specification limits defined per ICH Q3A guidelines. Stability studies assess its formation under thermal and hydrolytic stress, while accurate quantitation at low ppm levels is critical to ensure API purity and regulatory compliance.